Comorbid Psoriasis and Metabolic Syndrome: Clinical Implications and Optimal Management

References

• Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385. doi:10.1038/jid.2012.339
   PubMed Web of Science ®Google Scholar
• Augustin M, Radtke MA, Glaeske G, et al. Epidemiology and comorbidity in children with psoriasis and atopic eczema. Dermatology. 2015;231(1):35–40. doi:10.1159/000381913
   PubMed Web of Science ®Google Scholar
• Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev. 2008;29(7):777–822. doi:10.1210/er.2008-0024
   PubMed Web of Science ®Google Scholar
• Singh S, Young P, Armstrong AW. Relationship between psoriasis and metabolic syndrome: a systematic review. G Ital Dermatol Venereol. 2016;151(6):663–677.
   PubMed Web of Science ®Google Scholar
• Chan WMM, Yew YW, Theng TSC, Liew CF, Oon HH. Prevalence of metabolic syndrome in patients with psoriasis: a cross-sectional study in Singapore. Singapore Med J. 2020;61(4):194–199. doi:10.11622/smedj.2019152
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Nilsson PM. The metabolic syndrome: a glance at its history. J Hypertens. 2006;24(4):621–626. doi:10.1097/01.hjh.0000217840.26971.b6
   PubMed Web of Science ®Google Scholar
• Pinter A, Schwarz P, Gerdes S, et al. Biologic treatment in combination with lifestyle intervention in moderate to severe plaque psoriasis and concomitant metabolic syndrome: rationale and methodology of the METABOLyx Randomized Controlled Clinical Trial. Nutrients. 2021;13(9):3015. doi:10.3390/nu13093015
   PubMed Web of Science ®Google Scholar
• Ma C, Harskamp CT, Armstrong EJ, Armstrong AW. The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol. 2013;168(3):486–495. doi:10.1111/bjd.12101
   PubMed Web of Science ®Google Scholar
• Wohltmann W. JAAD Game Changers: psoriasis and the risk of diabetes: a prospective population-based cohort study. J Am Acad Dermatol. 2019;81(6):1459. doi:10.1016/j.jaad.2019.06.1296
   PubMed Web of Science ®Google Scholar
• Suárez-Fariñas M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C, Krueger JG. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol. 2012;132(11):2552–2564. doi:10.1038/jid.2012.184
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Boehncke S, Tobin AM, Kirby B. The “psoriatic march”: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303–307. doi:10.1111/j.1600-0625.2011.01261.x
   PubMed Web of Science ®Google Scholar
• Masson W, Lobo M, Molinero G. Psoriasis and cardiovascular risk: a comprehensive review. Adv Ther. 2020;37(5):2017–2033. doi:10.1007/s12325-020-01346-6
   PubMed Web of Science ®Google Scholar
• Lai YC, Yew YW. Psoriasis as an independent risk factor for cardiovascular disease: an epidemiologic analysis using a national database. J Cutan Med Surg. 2016;20(4):327–333. doi:10.1177/1203475415602842
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Papp KA, Lynde CW. Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol. 2018;32(7):1111–1119. doi:10.1111/jdv.14868
   PubMed Web of Science ®Google Scholar
• Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. doi:10.3390/ijms20061475
   PubMed Web of Science ®Google Scholar
• Kakarala CL, Hassan M, Belavadi R, et al. Beyond the skin plaques: psoriasis and its cardiovascular comorbidities. Cureus. 2021;13(11):e19679. doi:10.7759/cureus.19679
   PubMed Web of Science ®Google Scholar
• Lockshin B, Balagula Y, Merola JF. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol. 2018;79(2):345–352. doi:10.1016/j.jaad.2018.02.040
   PubMed Web of Science ®Google Scholar
• Bajaj S, Mandal S, Singh KG, Prajapati R. Metabolic diseases and associated complications in patients with psoriasis. J Assoc Physicians India. 2020;68(10):44–46.
   PubMedGoogle Scholar
• Hillary T, Lambert J. The use of metrics in daily practice and the perception of psoriasis-associated comorbidities: discrepancies between research and real-world. Psoriasis. 2021;11:169–175. doi:10.2147/ptt.S341215
   PubMed Web of Science ®Google Scholar
• Egan BM, Kjeldsen SE, Grassi G, Esler M, Mancia G. The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard? J Hypertens. 2019;37(6):1148–1153. doi:10.1097/hjh.0000000000002021
   PubMed Web of Science ®Google Scholar
• Bhagavathula AS, Shah SM, Suliman A, Oulhaj A, Aburawi EH. Hypertension control and guideline-recommended target blood pressure goal achievement at an early stage of hypertension in the UAE. J Clin Med. 2021;11(1):47. doi:10.3390/jcm11010047
   PubMed Web of Science ®Google Scholar
• Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073–1113. doi:10.1016/j.jaad.2018.11.058
   PubMed Web of Science ®Google Scholar
• Wu S, Han J, Li WQ, Qureshi AA. Hypertension, antihypertensive medication use, and risk of psoriasis. JAMA Dermatol. 2014;150(9):957–963. doi:10.1001/jamadermatol.2013.9957
   PubMed Web of Science ®Google Scholar
• Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244–1250. doi:10.1001/archdermatol.2012.2502
   PubMed Web of Science ®Google Scholar
• Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52(2):262–267. doi:10.1016/j.jaad.2004.06.017
   PubMed Web of Science ®Google Scholar
• Mosca M, Hong J, Hadeler E, et al. Psoriasis and cardiometabolic comorbidities: an evaluation of the impact of systemic treatments in randomized clinical trials. Dermatol Ther (Heidelb). 2021;11(5):1497–1520. doi:10.1007/s13555-021-00590-0
   PubMed Web of Science ®Google Scholar
• Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212. doi:10.1111/jdv.13854
   PubMed Web of Science ®Google Scholar
• de Jesus Janet M. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128 Suppl 5(Suppl5):S213–S256. doi:10.1542/peds.2009-2107C
   PubMedGoogle Scholar
• Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159(4):895–902. doi:10.1111/j.1365-2133.2008.08707.x
   PubMed Web of Science ®Google Scholar
• Arnett DK, Blumenthal RS, Albert MA. Correction to: 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2020;141(16):e773. doi:10.1161/cir.0000000000000770
   PubMed Web of Science ®Google Scholar
• Chat VS, Uppal SK, Kearns DG, Han G, Wu JJ. Translating the 2019 AAD-NPF guidelines of care for psoriasis with attention to comorbidities. Cutis. 2021;108(2s):7–11. doi:10.12788/cutis.0309
   PubMedGoogle Scholar
• Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122(1):198–208. doi:10.1542/peds.2008-1349
   PubMed Web of Science ®Google Scholar
• Osier E, Wang AS, Tollefson MM, et al. Pediatric psoriasis comorbidity screening guidelines. JAMA Dermatol. 2017;153(7):698–704. doi:10.1001/jamadermatol.2017.0499
   PubMed Web of Science ®Google Scholar
• Paller AS, Mercy K, Kwasny MJ, et al. Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study. JAMA Dermatol. 2013;149(2):166–176. doi:10.1001/jamadermatol.2013.1078
   PubMed Web of Science ®Google Scholar
• Boccardi D, Menni S, La Vecchia C, et al. Overweight and childhood psoriasis. Br J Dermatol. 2009;161(2):484–486. doi:10.1111/j.1365-2133.2009.09276.x
   PubMed Web of Science ®Google Scholar
• Thomas J, Parimalam K. Treating pediatric plaque psoriasis: challenges and solutions. Pediatric HealthMed Ther. 2016;7:25–38. doi:10.2147/phmt.S75834
   PubMed Web of Science ®Google Scholar
• Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201. doi:10.1016/j.jaad.2019.08.049
   PubMed Web of Science ®Google Scholar
• Skilton MR, Moulin P, Sérusclat A, Nony P, Bonnet F. A comparison of the NCEP-ATPIII, IDF and AHA/NHLBI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: evidence for sex-specific differences. Atherosclerosis. 2007;190(2):416–422. doi:10.1016/j.atherosclerosis.2006.02.019
   PubMed Web of Science ®Google Scholar
• Gisondi P, Cazzaniga S, Chimenti S, et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. J Eur Acad Dermatol Venereol. 2013;27(1):e30–e41. doi:10.1111/j.1468-3083.2012.04450.x
   PubMed Web of Science ®Google Scholar
• Malhotra A, Shafiq N, Rajagopalan S, Dogra S, Malhotra S. Thiazolidinediones for plaque psoriasis: a systematic review and meta-analysis. Evid Based Med. 2012;17(6):171–176. doi:10.1136/ebmed-2011-100388
   PubMedGoogle Scholar
• DeBoer MD. Assessing and managing the metabolic syndrome in children and adolescents. Nutrients. 2019;11(8):1788. doi:10.3390/nu11081788
   PubMed Web of Science ®Google Scholar
• Bronckers IM, Paller AS, van Geel MJ, van de Kerkhof PC, Seyger MM. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Paediatr Drugs. 2015;17(5):373–384. doi:10.1007/s40272-015-0137-1
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32 Suppl 1(Suppl1):S62–S67. doi:10.2337/dc09-S062
   PubMed Web of Science ®Google Scholar
• Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):147–151. doi:10.2340/00015555-0770
   PubMed Web of Science ®Google Scholar
• Kwa L, Kwa MC, Silverberg JI. Cardiovascular comorbidities of pediatric psoriasis among hospitalized children in the United States. J Am Acad Dermatol. 2017;77(6):1023–1029. doi:10.1016/j.jaad.2017.08.034
   PubMed Web of Science ®Google Scholar
• Vandenbriele C, Sun Y, Criel M, et al. Dextran sulfate triggers platelet aggregation via direct activation of PEAR1. Platelets. 2016;27(4):365–372. doi:10.3109/09537104.2015.1111321
   PubMed Web of Science ®Google Scholar
• Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265.e19. doi:10.1016/j.jaad.2018.06.027
   PubMed Web of Science ®Google Scholar
• Stoll ML, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. Curr Opin Rheumatol. 2011;23(5):437–443. doi:10.1097/BOR.0b013e328348b278
   PubMed Web of Science ®Google Scholar
• Lewkowicz D, Gottlieb AB. Pediatric psoriasis and psoriatic arthritis. Dermatol Ther. 2004;17(5):364–375. doi:10.1111/j.1396-0296.2004.04039.x
   PubMedGoogle Scholar
• Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323(12):1175–1183. doi:10.1001/jama.2020.2298
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep. 2021;3(4):100305. doi:10.1016/j.jhepr.2021.100305
   PubMedGoogle Scholar
• Magdaleno-Tapial J, Valenzuela-Oñate C, Ortiz-Salvador JM, et al. Prevalence of non-alcoholic fatty liver and liver fibrosis in patients with moderate-severe psoriasis: a cross-sectional cohort study. Australas J Dermatol. 2020;61(2):105–109. doi:10.1111/ajd.13175
   PubMed Web of Science ®Google Scholar
• Ganzetti G, Campanati A, Molinelli E, Offidani A. Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: three different diseases on a unique background. World J Cardiol. 2016;8(2):120–131. doi:10.4330/wjc.v8.i2.120
   PubMed Web of Science ®Google Scholar
• Balak DMW, Piaserico S, Kasujee I. Non-Alcoholic Fatty Liver Disease (NAFLD) in patients with psoriasis: a review of the hepatic effects of systemic therapies. Psoriasis. 2021;11:151–168. doi:10.2147/ptt.S342911
   PubMed Web of Science ®Google Scholar
• Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: so far, so near. World J Hepatol. 2015;7(3):315–326. doi:10.4254/wjh.v7.i3.315
   PubMed Web of Science ®Google Scholar
• Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212–2224. doi:10.1016/s0140-6736(20)32511-3
   PubMed Web of Science ®Google Scholar
• Bath RK, Brar NK, Forouhar FA, Wu GY. A review of methotrexate-associated hepatotoxicity. J Dig Dis. 2014;15(10):517–524. doi:10.1111/1751-2980.12184
   PubMed Web of Science ®Google Scholar
• Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One. 2015;10(10):e0140908. doi:10.1371/journal.pone.0140908
   PubMed Web of Science ®Google Scholar
• Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389–398. doi:10.1016/s2468-1253(19)30039-1
   PubMed Web of Science ®Google Scholar
• Tollefson MM, Van Houten HK, Asante D, Yao X, Maradit Kremers H. Association of psoriasis with comorbidity development in children with psoriasis. JAMA Dermatol. 2018;154(3):286–292. doi:10.1001/jamadermatol.2017.5417
   PubMed Web of Science ®Google Scholar
• King D, Chandan JS, Thomas T, et al. The risk of later diagnosis of inflammatory bowel disease in patients with dermatological disorders associated with inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(11):1731–1739. doi:10.1093/ibd/izaa344
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Amin M, Lee EB, Tsai TF, Wu JJ. Psoriasis and co-morbidity. Acta Derm Venereol. 2020;100(3):adv00033. doi:10.2340/00015555-3387
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG. A test in context: lipid profile, fasting versus nonfasting. J Am Coll Cardiol. 2017;70(13):1637–1646. doi:10.1016/j.jacc.2017.08.006
   PubMed Web of Science ®Google Scholar
• Wan MT, Shin DB, Hubbard RA, Noe MH, Mehta NN, Gelfand JM. Psoriasis and the risk of diabetes: a prospective population-based cohort study. J Am Acad Dermatol. 2018;78(2):315–322.e1. doi:10.1016/j.jaad.2017.10.050
   PubMed Web of Science ®Google Scholar
• Roubille C, Richer V, Starnino T, et al. Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the Canadian dermatology-rheumatology comorbidity initiative. J Rheumatol. 2015;42(10):1767–1780. doi:10.3899/jrheum.141112
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European. Heart Journal. 2018;39(33):3021–3104. doi:10.1093/eurheartj/ehy339
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J. The metabolic syndrome–a new worldwide definition. Lancet. 2005;366(9491):1059–1062. doi:10.1016/S0140-6736(05)67402-8
   PubMed Web of Science ®Google Scholar
• Jensen P, Zachariae C, Christensen R, et al. Effect of weight loss on the cardiovascular risk profile of obese patients with psoriasis. Acta Derm Venereol. 2014;94(6):691–694. doi:10.2340/00015555-1824
   PubMed Web of Science ®Google Scholar
• Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423–441. doi:10.1007/s40265-014-0191-y
   PubMed Web of Science ®Google Scholar
• Loomis AK, Kabadi S, Preiss D, et al. Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record prospective studies. J Clin Endocrinol Metab. 2016;101(3):945–952. doi:10.1210/jc.2015-3444
   PubMed Web of Science ®Google Scholar
• Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64(2):319–334. doi:10.1097/mpg.0000000000001482
   PubMed Web of Science ®Google Scholar